ClinicalTrials.gg
CompletedNCT04493541Updated May 9, 2023

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

A Phase 1 interventional study of BMS-986256 and BMS-986256 Placebo in Lupus Erythematosus, Cutaneous, sponsored by Bristol-Myers Squibb. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Lupus Erythematosus, Cutaneous with a site in Germany — 3 open to participants now, 7 under way, 5 of them phase 3. Lupus Erythematosus, Cutaneous · Germany.

Enrollment
15th of 20
13 · median 28
Started
2020
with 1 other
Phase 1
4 of 23
none open now
Registered
12th of 23
by date
Lead sponsor
3 of 23
Bristol-Myers Squibb

Among the 23 studies in Lupus Erythematosus, Cutaneous with a site in Germany, this one is the 15th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 1, and was the 12th registered.

Lupus Erythematosus, Cutaneous

67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.

Browse Lupus Erythematosus, Cutaneous studies →

Open to participants now

3 of the 23 studies in Lupus Erythematosus, Cutaneous with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Lupus Erythematosus, Cutaneous with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and drug levels of BMS-986256 in participants with cutaneous lupus erythematosus.

03

Conditions studied

  • Lupus Erythematosus, Cutaneous
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

a) Must have one of following diagnoses: i) Meet European League Against Rheumatoid (EULAR)/American College of Rheumatology 2019 Classification Criteria for systemic lupus erythematosus (SLE) OR ii) -proven acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE), or discoid lupus erythematosus (DLE): Participants without a concurrent SLE diagnosis are eligible b) Active cutaneous lupus disease, defined as a modified Cutaneous Lupus Erythematosus Disease Area and Severity Index- Activity (mCLASI-A) score ≥ 6 c) Active cutaneous lupus skin lesion(s) amenable to biopsy

  • Women of (WOCBP) and men must agree to follow instructions for method(s) of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Active severe or unstable neuropsychiatric SLE
  • Active, severe Lupus Nephritis (LN)
  • Any British Isles Lupus Assessment Group (BILAG) A or B, unless within the constitutional, musculoskeletal and/or mucocutaneous domains

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    BMS-986256

    Drug: BMS-986256

  • Placebo comparator
    Placebo

    Other: BMS-986256 Placebo

Interventions

  • Specified Dose on Specified Days

  • OtherBMS-986256 Placebo

    Specified Dose on Specified Days

06

What researchers measure

Primary outcomes

  1. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 24 weeks

  2. Incidence of Adverse Events (AEs)

    Time frame: Up to 20 weeks

  3. Number of laboratory test abnormalities: Hematology

    Time frame: Up to 20 weeks

  4. Number of laboratory test abnormalities: Urinalysis

    Time frame: Up to 20 weeks

  5. Number of laboratory test abnormalities: Clinical Chemistry

    Time frame: Up to 20 weeks

  6. Incidence of clinically significant changes in physical examination findings

    Time frame: Up to 20 weeks

  7. Incidence of clinically significant changes in vital signs: Body temperature

    Time frame: Up to 20 weeks

  8. Incidence of clinically significant changes in vital signs: Respiratory rate

    Time frame: Up to 20 weeks

  9. Incidence of clinically significant changes in vital signs: Blood pressure

    Time frame: Up to 20 weeks

  10. Incidence of clinically significant changes in vital signs: Heart rate

    Time frame: Up to 20 weeks

  11. Incidence of clinically significant changes in Electrocardiogram (ECG) parameters

    Time frame: Up to 20 weeks

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986256

    Time frame: Up to 20 weeks

  2. Time to maximum concentration (Tmax) of BMS-986256

    Time frame: Up to 20 weeks

  3. Trough observed plasma concentration (Ctrough) of BMS-986256

    Time frame: Up to 20 weeks

  4. Area under the concentration-time curve over the dosing interval (AUC (TAU)) of BMS-986256

    Time frame: Up to 20 weeks

  5. Maximum observed plasma concentration (Cmax) of metabolite BMT-271199

    Time frame: Up to 20 weeks

  6. Time to maximum concentration (Tmax) of metabolite BMT-271199

    Time frame: Up to 20 weeks

  7. Trough observed plasma concentration (Ctrough) of metabolite BMT-271199

    Time frame: Up to 20 weeks

  8. Area under the concentration-time curve over the dosing interval (AUC (TAU)) of metabolite BMT-271199

    Time frame: Up to 20 weeks

07

Study locations

1 site
  • Local Institution - 0001
    Berlin, 10117, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Apr 2023, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2020
First posted
Jul 30, 2020
StartActual
Aug 26, 2020
Primary completionActual
Apr 21, 2023
CompletionActual
Apr 21, 2023
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04493541
Responsible party
Sponsor
First posted
Jul 30, 2020
Start date
Aug 26, 2020
Primary completion
Apr 21, 2023
Completion
Apr 21, 2023
Last update
May 9, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimetoran

Start the discussion